Nugmanova, Damilya
Sokolova, Lyudmila
Feshchenko, Yuriy
Iashyna, Liudmila
Gyrina, Olga
Malynovska, Katerina
Mustafayev, Ilgar
Aliyeva, Gulzar
Makarova, Janina
Vasylyev, Averyan
Tariq, Luqman
Funding for this research was provided by:
GlaxoSmithKline
Article History
Received: 3 December 2017
Accepted: 13 June 2018
First Online: 5 July 2018
Ethics approval and consent to participate
: The study was reviewed and approved by Independent Ethic Committee in Kazakhstan (Central Commission for Ethics at the Ministry of Health of the Republic of Kazakhstan) and by Local Ethic Committees in Kazakhstan, Azerbaijan and Ukraine (Ethic Committee at Semey State Medical University, Almaty, Kazakhstan; Ethic Committee at Scientific Research Institute of Lung Diseases in Baku, Azerbaijan; Commission for Ethics at National Institute of Phthisiology and Pulmonology F.G. Yanovsky of NAMS, Kiev, Ukraine; Commission for Ethics at Center for Primary Health Care #2 of Shevchenko District, Kiev, Ukraine), according to the local legal requirements. Written informed consent was obtained from each participant before any procedures or data collection related to the study.
: Not applicable.
: The study was sponsored by GlaxoSmithKline (GSK) marketing a number of treatments for COPD, Allergic Rhinitis, and Asthma.D. Nugmanova, L. Sokolova, Y. Feshchenko, L. Iashyna, O. Gyrina, I. Mustafayev and G. Aliyeva report grants from GlaxoSmithKline, during the conduct of the study; personal fees from GSK, outside the submitted work; .J. Makarova, K. Malynovska are employees of GlaxoSmithKline. A. Vasylyev and L. Tariq are GSK employees and shareholder.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.